Don't wait! Investigate the heart murmur.

Cardalis° (spironolactone and benazepril hydrochloride chewable tablets)

					/
	DEFINITION	CLINICAL SIGNS	DIAGNOSTICS	DIETARY SODIUM	MEDICATIONS
A	Dog breeds at high risk	None	Physical Examination	No specific dietary recommendations	None
Bı	MMVD with no (or mild) cardiac enlargement	Heart Murmur	Murmur intensity: 1-2/6 VHS: <10.5 (breed adjusted) with echo, <11.5 without echo Echo: LA: Ao <1.6; LVIDDN <1.7 Baseline lab work, NIBP, RRR	No specific dietary recommendations	None
B ₂	Cardiac enlargemen but no history of CH		Murmur intensity: ≥ 3/6 VHS >10.5 (breed adjusted) with echo, >11.5 without echo Echo: LA:Ao ≥ 1.6; LVIDDN ≥ 1.7 Baseline lab work, NIBP, RRR	Mild restriction	Pimobendan
С	Current or past clinical signs of CHF	Acute (tachypnea, restlessness, respiratory distress, cough) or stabilized CHF	Stabilize prior to diagnostic workup Minimum database Radiographs to assess pulmonary edema	Modest restriction	BEGIN QUAD THERAPY ACE inhibitors
D	Current or past clinic signs of CHF Refractory to standa medications/doses	rd Acute or stabilized	Refractory to the standard treatments for Stage C patients Minimum database if patient stability allows Furosemide >8mg/kg/day or equivalent torsemide	Modest restriction	(e.g., Benazepril) Pimobendan* Spironolactone
Body Weight	5.5 - 10.9 lbs 2.5 - 5 kg 11 - 21.9 lbs 5 - 10) kg 22 - 43.9 lbs 10 - 20 kg 44 - 87.9 lbs 2	20 - 40 kg 88 - 131.9 lbs 40 - 60 kg 132 - 176 lbs 60 - 80 kg Chart	summarizes 201	9 ACVIM guidelines for

bouy weight	5.5 - 10.9 lbs 2.5 - 5 kg	11 - 21.9 lbs 5 - 10 kg	22 - 43.9 lbs 10 - 20 kg	44 - 87.9 lbs 20 - 40 kg	88 - 131.9 lbs 40 - 60 kg	132 - 176 IDS 60 - 80 Kg
CARDALIS [™] 20/2.5 20 mg Spironolactone 2.5 mg Benazepril HCl				0 0 0 0	0 0 0 0	
CARDALIS [™] 40/5 40 mg Spironolactone 5 mg Benazepril HCl					0 0 0 0 0	
CARDALIS [™] 80/10 80 mg Spironolactone 10 mg Benazepril HCl					-	88

Chart summarizes 2019 ACVIM guidelines for the diagnosis and treatment of MMVD in dogs¹



See attached product insert for more information on CARDALIS™

Important Safety Information:

Do not administer in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not use in dogs with hypoadrenocorticism (Addison's disease), hyperkalemia or hyponatremia. Do not use in dogs with known hypersensitivity to ACE inhibitors or spironolactone. The safety and effectiveness of concurrent therapy of Cardalis[™] administration should begin after pulmonary edema is stabilized. Regular monitoring of renal function and serum potassium levels is recommended. Common side effects from a field study include anorexia, vomiting, lethargy, diarrhea and renal insufficiency.


*In 2019, the ACVIM published new guidelines recommending a quadruple therapy approach for the treatment of CHF in dogs. The safety and efficacy of CARDALIS[™] has not been investigated with pimobendan. 1. Keene, BW, Atkins, CE, Bonagura, JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019; 33: 1127–1140. https:// doi.org/10.1111/jvim.15488

CARDALIS™ RESTING RESPIRATORY RATE APP



Monitor Your Heart Dog









Cardalis° (spironolactone and benazepril hydrochloride chewable tablets)

©2024 Ceva Animal Health, LLC. | CARDALIS and the CARDALIS logo trademarks are the property of Ceva Santé Animale S.A. | CRD-106-24v3